OBJECTIVE: To investigate the relationship between synovial vascularity and progression of structural bone damage in each finger joint in patients with rheumatoid arthritis (RA) and to demonstrate synovial vascularity as a potential therapeutic marker. METHODS: We studied 250 metacarpophalangeal (MCP) and 250 proximal interphalangeal (PIP) joints of 25 patients with active RA who were administered adalimumab or tocilizumab. Patients were examined with clinical and laboratory assessments. Power Doppler sonography was performed at baseline and at the fourth and eighth weeks. Synovial vascularity was evaluated according to quantitative measurement. Hand and foot radiography was performed at baseline and the twentieth week. RESULTS: Clinical indices such as the 28-joint Disease Activity Score, the Clinical Disease Activity Index, and the Simplified Disease Activity Index were significantly decreased by biologic agents. The MCP and PIP joints with no response in synovial vascularity between baseline and the eighth week (vascularity improvement of ≤70% at the eighth week) showed a higher risk of radiographic progression compared with responsive joints (vascularity improvement of >70% at the eighth week; relative risk 2.33-9). Radiographic progression at the twentieth week was significantly lower in responsive joints than in nonresponsive joints. CONCLUSION: The improvement of synovial vascularity following treatment with biologic agents led to suppression of radiographic progression of RA in each finger joint. The alteration in synovial vascularity numerically reflected therapeutic efficacy. Using vascularity as a marker to determine the most suitable therapeutic approach would be beneficial for patients with active RA.
OBJECTIVE: To investigate the relationship between synovial vascularity and progression of structural bone damage in each finger joint in patients with rheumatoid arthritis (RA) and to demonstrate synovial vascularity as a potential therapeutic marker. METHODS: We studied 250 metacarpophalangeal (MCP) and 250 proximal interphalangeal (PIP) joints of 25 patients with active RA who were administered adalimumab or tocilizumab. Patients were examined with clinical and laboratory assessments. Power Doppler sonography was performed at baseline and at the fourth and eighth weeks. Synovial vascularity was evaluated according to quantitative measurement. Hand and foot radiography was performed at baseline and the twentieth week. RESULTS: Clinical indices such as the 28-joint Disease Activity Score, the Clinical Disease Activity Index, and the Simplified Disease Activity Index were significantly decreased by biologic agents. The MCP and PIP joints with no response in synovial vascularity between baseline and the eighth week (vascularity improvement of ≤70% at the eighth week) showed a higher risk of radiographic progression compared with responsive joints (vascularity improvement of >70% at the eighth week; relative risk 2.33-9). Radiographic progression at the twentieth week was significantly lower in responsive joints than in nonresponsive joints. CONCLUSION: The improvement of synovial vascularity following treatment with biologic agents led to suppression of radiographic progression of RA in each finger joint. The alteration in synovial vascularity numerically reflected therapeutic efficacy. Using vascularity as a marker to determine the most suitable therapeutic approach would be beneficial for patients with active RA.
Authors: Veena K Ranganath; Ami Ben-Artzi; Erin Duffy; Jenny Brook; Mihaela Taylor; Soo Choi; Harold Paulus; David A Elashoff Journal: Rheumatology (Oxford) Date: 2015-08-27 Impact factor: 7.580
Authors: Maxime Dougados; Valérie Devauchelle-Pensec; Jean François Ferlet; Sandrine Jousse-Joulin; Maria-Antonietta D'Agostino; Marina Backhaus; Jacques Bentin; Gérard Chalès; Isabelle Chary-Valckenaere; Philip Conaghan; Richard J Wakefield; Fabien Etchepare; Frédéric Etcheparre; Philippe Gaudin; Walter Grassi; Désirée van der Heijde; Xavier Mariette; Esperanza Naredo; Marcin Szkudlarek Journal: Ann Rheum Dis Date: 2012-06-07 Impact factor: 19.103
Authors: Stefano Alivernini; Barbara Tolusso; Luca Petricca; Laura Bui; Gabriele Di Sante; Giusy Peluso; Roberta Benvenuto; Anna Laura Fedele; Franco Federico; Gianfranco Ferraccioli; Elisa Gremese Journal: Ann Rheum Dis Date: 2017-01-24 Impact factor: 19.103
Authors: Tina M Backhaus; Sarah Ohrndorf; Herbert Kellner; Johannes Strunk; Wolfgang Hartung; Horst Sattler; Christof Iking-Konert; Gerd R Burmester; Wolfgang A Schmidt; Marina Backhaus Journal: Ann Rheum Dis Date: 2012-09-06 Impact factor: 19.103
Authors: Maxime M A Verhoeven; Janneke Tekstra; Anne C A Marijnissen; Anna J L Meier; Antonius A A Westgeest; Floris P J G Lafeber; Johannes W G Jacobs; Jacob M van Laar; Paco M J Welsing Journal: Rheumatol Adv Pract Date: 2021-01-28